Pharma & Biotech - Page 7

Ameer Ali, senior director of manufacturer operations and data services at Cencora, is urging trading partners to begin preparing their systems for the NDC-12 transition long before the rule takes effect. Ali

Roche has once again swept all four versions of a major neurology corporate reputation ranking compiled by patient advocacy research organisation PatientView. The Swiss pharmaceutical giant secured top position among companies that

AstraZeneca (AZN) has launched a new marketing campaign for its Breztri inhaler, targeting asthma patients for the first time after years of COPD-focused advertising. The campaign marks a significant shift, as Breztri

Major pharmaceutical companies including Roche, GSK, and Novartis are at the centre of a flurry of deal-making and drug pricing agreements reshaping the industry landscape. GSK moved first among the late movers

UCB’s Bimzelx emerged as a notable newcomer in August’s pharmaceutical television advertising rankings, claiming ninth place among the top spending drug brands. The psoriasis and psoriatic arthritis medication displaced Intra-Cellular Therapies’ Caplyta

Daiichi Sankyo subsidiary American Regent is recalling three lots of generic epinephrine injection vials distributed across the United States amid concerns over particulate contamination and packaging failures. The recall follows customer complaints

Ionis Pharmaceuticals has secured FDA approval for Zanvastro, marking a landmark moment as the first disease-modifying therapy ever cleared for Alexander disease. The approval arrived more than two weeks ahead of its

The Trump administration has announced nine new Most-Favored-Nation agreements with pharmaceutical manufacturers, significantly broadening the reach of the pricing programme. The latest additions bring the total number of companies participating in the

Over 600,000 seniors have enrolled in the Medicare GLP-1 Bridge program within just two months of its July 2026 launch, according to the White House. The program, which emerged from the Trump

Akeso and Summit Therapeutics’ (SMMT) ivonescimab has cleared another clinical milestone, meeting its overall survival endpoint in the trial that first put the drug on the map. The PD-1xVEGF bispecific antibody generated